Teijin Pharma Launches Febuxostat To Manage Hyperuricemia In Gout Patients

Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, have began marketing the product in Europe under the brand name Adenuric, starting in France on March 8.

TMX-67 is an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase. A novel drug with a structure completely different from that of allopurinol, TMX-67 lowers the level of uric acid in the blood of hyperuricemic patients suffering from gout. TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.

Reportedly, Adenuric will be further launched by Menarini, which holds the marketing rights in 41 European countries, in the UK on March 11, Germany on March 15 and Ireland on March 29. Additional launches in other European countries are expected.

Earlier, Teijin Pharma had signed an exclusive license agreement with Ipsen in July 2003, for the development and marketing of TMX-67 in Europe. Following EMEA approval in April 2008, Ipsen signed in October 2009 an exclusive sublicense agreement with Menarini.